CCTV News: Before the arrival of the Little Cold Solar Period, the Chinese Center for Disease Control and Prevention also released the national monitoring of acute respiratory infectious disease sentinels in the 52nd week of 2024 (December 23-December 29). Analysis of monitoring results shows that at present, acute respiratory infectious diseases generally show a continuous upward trend, and the trend of infection caused by different pathogens varies, and the positive rate of influenza viruses has increased rapidly.

The positive pathogens tested by outpatient emergency hospitals are mainly influenza virus, human metapneumovirus, and rhinovirus. The positive pathogens tested by hospitalized severe acute respiratory infection cases are mainly influenza virus, Mycoplasma pneumoniae, and human metapneumovirus. In other words, influenza is one of the most important pathogens in both outpatient and emergency cases or severe hospitalization cases. There are regional differences between the north and the south and differences between people of different age groups.

The levels of influenza activity vary between provinces, and the rise in northern provinces is slightly obvious, but it is still lower than the same period last year. Among the cases aged 0-4, the positive rate of respiratory syncytial virus and among the cases aged 14 and under, the positive rate of human metapneumovirus showed a fluctuating and upward trend, and the upward trend in northern provinces was more obvious.

The positive rate of Mycoplasma pneumonia in northern provinces continues to decline, while Mycoplasma pneumonia infection in southern provinces is still at a low level. The national rhinovirus positive rate continues to decline, and the adenovirus positive rate shows a fluctuating and downward trend.

The current influenza viruses are more than 99% of the type A H1N1 subtype

In addition, the monitoring results of the Chinese Center for Disease Control and Prevention also show that the current positive rate of influenza viruses in the south and north is more than 99% of the current H1N1 subtype influenza viruses. With the increase in the number of influenza infections, the sales of anti-influenza drugs have also continued to grow recently, especially a drug called mabaloxavir is sought after. Is Mabalosavevir really suitable for everyone? What is the difference between it and another flu drug oseltamivir?

Oseltavir and mabaloxavir are currently proven to be used to treat influenza A and influenza B infections.

The two have different medication mechanisms and different administration methods. Oseltamivir needs to be taken twice a day for five consecutive days; mabaloxavir only needs to be given once throughout the course of the disease.

At present, oseltamivir capsules and granules can be used in children over 1 year old and adults. The dry suspension is younger, and the dosage is given in children based on their weight. Mabalovsavir is currently only approved for use in children and adults over 5 years old and weighing over 20 kg.

Doctors remind that infants and young children should give priority to seeking medical treatment in a timely manner after infection, and medication safety should be given under the guidance of a doctor, including pregnancy and breastfeeding patients.